New insights into facial flushing and erythema in rosacea

2020 ◽  
Keyword(s):  
Facial Flushing

The Use of Desmopressin Acetate (DDAVP) as a Test of the Fibrinolytic Capacity of Patients – Analysis of Responders and Non-Responders

1982 ◽  
Vol 48 (02) ◽  
pp. 156-161 ◽  
Author(s):  
E J P Brommer ◽  
M M Barrett-Bergshoeff ◽  
R A Allen ◽  
I Schicht ◽  
R M Bertina ◽  
...  
Keyword(s):  
Renal Insufficiency ◽  
Plasminogen Activator ◽  
Vascular Endothelium ◽  
Fibrinolytic Activity ◽  
Baseline Level ◽  
Poor Response ◽  
Facial Flushing ◽  
Spontaneous Thrombosis ◽  
Type Iv ◽  
Fibrinolytic Capacity

SummaryIntravenous infusion of desmopressin (DDAVP, 0.4 μg/kg b.w. in 12’) causes an increase in the level of extrinsic plasminogen activator, measured in plasma euglobulin fractions with added C1-inactivator on fibrin plates. A poor response or no response at all was elicited in two out of 21 patients with spontaneous thrombosis, 18/38 with hyperlipoproteinaemia and 10/14 with terminal renal insufficiency requiring haemodialysis.Haemodilution during the first 30’ after starting the DDAVP-infusion occurred both in responders and in non-responders; so did haemodynamic reactions: increase in heart rate, drop in diastolic blood pressure, facial flushing. The rise of fibrinolytic activity was shown not to be associated with decreased hepatic blood flow. Normal factor VIII-rises in “non-responders” indicate the responsiveness of the receptive organs, including the hypothalamus, to DDAVP.Despite a normal baseline level of fibrinolytic activity in the blood, as occurs for instance in terminal renal insufficiency, the vascular endothelium may be refractory to stimulation. In some patients, especially in type IV hyperlipoproteinaemia, a selective defect of the release of plasminogen activator is postulated. In subjects with low fibrinolytic activity at rest, as observed in spontaneous thromboembolism and in hypertriglyceridaemia, the failure to release plasminogen activator upon stimulation with DDAVP might be a consequence of an impairment of synthesis as well.

scholarly journals Case 2: Unilateral facial flushing with eating

2009 ◽  
Vol 14 (6) ◽  
pp. 371-373 ◽  
Author(s):  
Joseph Lam ◽  
Julie Milligan
Keyword(s):  
Facial Flushing

Facial Flushing Due to Recurrent Bronchial Carcinoid

2007 ◽  
Vol 83 (3) ◽  
pp. 1196-1197 ◽  
Author(s):  
Somshekar Ganti ◽  
Richard Milton ◽  
Leslie Davidson ◽  
Andrew Thorpe
Keyword(s):  
Bronchial Carcinoid ◽  
Facial Flushing

scholarly journals New trends in botulinum toxin use in dermatology

2018 ◽  
pp. 277-282 ◽  
Author(s):  
Stefania Guida ◽  
Francesca Farnetani ◽  
Steven P. Nisticò ◽  
Caterina Giorgio Mariarosaria ◽  
Graziella Babino ◽  
...  
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Neurotoxin ◽  
Current Knowledge ◽  
Hypertrophic Scars ◽  
Skin Disorders ◽  
Facial Flushing ◽  
Cutaneous Lesions ◽  
Raynaud Phenomenon ◽  
Skin Conditions ◽  
Review Current

Background: Recent studies have highlighted new botulinum neurotoxin (BoNT) applications in the field of dermatology. Objective: To review current knowledge of BoNT use in dermatology. Methods: The literature of the last 5 years has been reviewed. Results: We describe interesting protocols of BoNT treatment for hyperhidrosis (HH), hypertrophic scars and keloids, Raynaud phenomenon, facial flushing, oily skin, psoriasis, Hailey-Hailey disease, and cutaneous lesions like painful lesions and periorbital syringomas. Conclusions: Several skin conditions eligible for BoNT treatment have been described. After the wide application for HH treatment, scars as well as vascular and inflammatory skin disorders, oily skin and cutaneous lesions represent fields of application of BoNT.

scholarly journals Clonidine and facial flushing in rosacea.

BMJ ◽  
1977 ◽  
Vol 1 (6053) ◽  
pp. 105-105 ◽  
Author(s):  
W J Cunliffe ◽  
B Dodman ◽  
J G Binner
Keyword(s):  
Facial Flushing

scholarly journals The efficacy and safety of antimuscarinics for the prevention or treatment of catheter-related bladder discomfort: a systematic review and meta-analysis of randomized controlled trials

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Zhongbao Zhou ◽  
Yuanshan Cui ◽  
Xiaoyi Zhang ◽  
Youyi Lu ◽  
Zhipeng Chen ◽  
...  
Keyword(s):  
Systematic Review ◽  
Randomized Controlled Trials ◽  
Meta Analysis ◽  
Postoperative Nausea And Vomiting ◽  
Control Group ◽  
Controlled Trials ◽  
Efficacy And Safety ◽  
Facial Flushing ◽  
Blurred Vision ◽  
Randomized Controlled

Abstract Objectives This meta-analysis aimed to evaluate the efficacy and safety of antimuscarinics for the prevention or treatment of catheter related bladder discomfort (CRBD). Methods The MEDLINE, EMBASE, and Cochrane Controlled Trials Register (from 1987 to July 2021) were used to search randomized controlled trials. The PRISMA checklists were followed. RevMan5.4.0 was used for statistical analysis. Results Eleven studies involving 1165 patients were involved in the analysis. The study reported that the incidence of CRBD observed in the antimuscarinics group was significantly lower than that of the control group at 0-, 1-, 2-, and 6-h after drug therapy (P = 0.001, P < 0.0001, P = 0.0005, and P = 0.001, respectively). For side effects, there were not statistical differences between the antimuscarinics group and the control group, mainly including dry mouth (risk ratio (RR) = 1.31, 95% confidence interval (CI) = 0.95 to 1.80, P = 0.09), postoperative nausea and vomiting (RR = 1.02, 95% CI = 0.55 to 1.90, P = 0.87), facial flushing (RR = 1.06, 95% CI = 0.43 to 2.61, P = 0.90), and blurred vision (RR = 0.95, 95% CI = 0.35 to 2.58, P = 0.91). Besides, rescue analgesics were required less in the antimuscarinics group than in the control group (RR = 0.51, 95% CI = 0.32 to 0.80, P = 0.003). Conclusions Compared with the control group, the antimuscarinics group had a significant improvement on CRBD, the patients were well tolerated and the use rate of rescue analgesics was low.

Sign in / Sign up

Export Citation Format

Share Document